Bradykinin Symposium 2026

Sep 3 - Sep 4, 2026

  • Title: Modelling human, rat, and humanized bradykinin B2 receptor-deucrictibant complexes in-silico
    Presenter: Niklas Piet Doering, Ph.D.
    Format: Oral Presentation
    Abstract ID: 158012
    Date, time: Thursday, September 3, 2:55-3:05 p.m. CEST (8:55-9:05 a.m. EDT)
  • Title: Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Regional Subgroup Analysis From the Phase 3 RAPIDe-3 Trial
    Presenter: Marc A. Riedl, M.D., M.S.
    Format: Oral Presentation
    Abstract ID: 158394
    Date, time: Friday, September 4, 9:20-9:30 a.m. CEST (3:20-3:30 a.m. EDT)
  • Title: Clinical Cardiovascular Safety Evaluation of Oral Deucrictibant
    Presenter: Brigitte Loenders, Ph.D.
    Format: Poster Presentation
    Abstract ID: 157799 
    Date, time: Friday, September 4, 4:05-4:45 p.m. CEST (10:05-10:45 a.m. EDT)
  • Title: Evaluating Safety Margins of the Use of Deucrictibant Immediate-Release Capsule in Combination With Deucrictibant Extended-Release Tablet
    Presenter: Juan Bravo, Ph.D.
    Format: Poster Presentation
    Abstract ID: 157800
    Date, time: Friday, September 4, 4:05-4:45 p.m. CEST (10:05-10:45 a.m. EDT)
  • Title: Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Poster Presentation
    Abstract ID: 157804
    Date, time: Friday, September 4, 4:05-4:45 p.m. CEST (10:05-10:45 a.m. EDT)
  • Title: CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema
    Presenter: Marcin Stobiecki, M.D., Ph.D.
    Format: Poster Presentation
    Abstract ID: 157807
    Date, time: Friday, September 4, 4:05-4:45 p.m. CEST (10:05-10:45 a.m. EDT)
  • Title: End Of Progression of Attack Manifestations With Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks in the Phase 3 RAPIDe-3 Trial
    Presenter: Henriette Farkas, M.D., Ph.D., D.Sc.
    Format: Poster Presentation
    Abstract ID: 158385
    Date, time: Friday, September 4, 4:05-4:45 p.m. CEST (10:05-10:45 a.m. EDT)
  • Title: End-of-Progression Using Patient Global Impression of Change Validation in RAPIDe-3
    Presenter: Danny M. Cohn, M.D., Ph.D.
    Format: Poster Presentation
    Abstract ID: 158405
    Date, time: Friday, September 4, 4:05-4:45 p.m. CEST (10:05-10:45 a.m. EDT) 
  • Title: LC-MS particle-based plasma proteomics in bradykinin-mediated angioedema
    Presenter: Jonathan DeGeer, Ph.D.
    Format: Poster Presentation
    Abstract ID: 158979
    Date, time: Friday, September 4, 4:05-4:45 p.m. CEST (10:05-10:45 a.m. EDT)
  • Title: The NHP Bradykinin Challenge Model Predicts Human Deucrictibant Efficacious Doses
    Presenter: Juan Bravo, Ph.D.
    Format: Poster Presentation
    Abstract ID: 159172
    Date, time: Friday, September 4, 4:05-4:45 p.m. CEST (10:05-10:45 a.m. EDT)